QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
NASDAQ:LPCN

Lipocine (LPCN) Stock Forecast, Price & News

$2.92
+0.09 (+3.18%)
(As of 10/3/2023 ET)
Compare
Today's Range
$2.79
▼
$3.03
50-Day Range
$2.83
▼
$5.10
52-Week Range
$2.76
▼
$10.33
Volume
15,259 shs
Average Volume
68,758 shs
Market Capitalization
$15.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$68.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Lipocine MarketRank™ Forecast

Analyst Rating
0.00 Rating Score
Upside/​Downside
2,228.8% Upside
$68.00 Price Target
Short Interest
Healthy
2.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Lipocine in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.70) to ($1.91) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.54 out of 5 stars

Medical Sector

887th out of 976 stocks

Pharmaceutical Preparations Industry

408th out of 447 stocks

See Top Rated MarketRank™ Stocks Here

LPCN stock logo

About Lipocine (NASDAQ:LPCN) Stock

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

LPCN Price History

LPCN Stock News Headlines

September 28, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)
September 19, 2023 | finance.yahoo.com
Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference
October 3, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
August 17, 2023 | stocknews.com
Looking for a Value Investment? Check out These 3 Pharma Stocks
August 16, 2023 | finance.yahoo.com
LPCN: Trial Results Improve Outlook
August 10, 2023 | finance.yahoo.com
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023
July 31, 2023 | finance.yahoo.com
LPCN: 1148 Shows Muscle Loss Reversal
July 27, 2023 | benzinga.com
Why Lipocine Stock Is Moving Higher Today?
October 3, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
July 27, 2023 | investorplace.com
Why Is Lipocine (LPCN) Stock Up 32% Today?
June 14, 2023 | finance.yahoo.com
Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference
June 7, 2023 | finance.yahoo.com
Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023
May 16, 2023 | msn.com
Lipocine stock dips after bridging study data of LPCN 1154 for postpartum depression
May 16, 2023 | finance.yahoo.com
Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression
May 12, 2023 | msn.com
Recap: Lipocine Q1 Earnings
May 11, 2023 | apnews.com
Lipocine: Q1 Earnings Snapshot
May 11, 2023 | finance.yahoo.com
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023
April 3, 2023 | finance.yahoo.com
First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154
March 16, 2023 | finance.yahoo.com
LPCN: 2022 Operational & Financial Update
March 10, 2023 | finance.yahoo.com
Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock
March 10, 2023 | finance.yahoo.com
Lipocine Announces Financial Results for the Year Ended December 31, 2022
January 16, 2023 | finance.yahoo.com
Is Lipocine Inc.'s (NASDAQ:LPCN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
January 5, 2023 | finance.yahoo.com
Lipocine to Present at Biotech Showcase
December 19, 2022 | finance.yahoo.com
Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis
November 9, 2022 | finance.yahoo.com
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022
November 3, 2022 | finance.yahoo.com
Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline
October 11, 2022 | finance.yahoo.com
Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference - Yahoo Finance
See More Headlines
Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Company Calendar

Last Earnings
8/10/2023
Today
10/03/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LPCN
CUSIP
N/A
CIK
1535955
Web
www.lipocine.com
Phone
(801) 994-7383
Fax
801-994-7388
Employees
15
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$68.00
High Stock Price Forecast
$68.00
Low Stock Price Forecast
$68.00
Forecasted Upside/Downside
+2,277.6%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.3807)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,760,000.00
Net Margins
N/A
Pretax Margin
-21,921.82%
Return on Equity
-36.05%
Return on Assets
-34.09%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
14.82
Quick Ratio
14.82

Sales & Book Value

Annual Sales
$500,000.00
Price / Sales
30.43
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.85 per share
Price / Book
0.42

Miscellaneous

Outstanding Shares
5,320,000
Free Float
5,040,000
Market Cap
$15.22 million
Optionable
Optionable
Beta
1.04

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Mahesh V. Patel Ph.D. (Age 66)
    Co-Founder, Interim Principal Financial Officer, Director, Pres & CEO
    Comp: $598.91k
  • Ms. Krista Fogarty (Age 55)
    Principal Accounting Officer & Corp. Controller
    Comp: $268.12k
  • Dr. Nachiappan Chidambaram Ph.D. (Age 53)
    Sr. VP of R&D
    Comp: $311.17k
  • Mr. Logan Morse (Age 53)
    VP of Sales, Marketing & Operations
  • Mr. Morgan R. Brown CPA (Age 55)
    CPA, M.B.A., MBA, Corp. Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













LPCN Stock - Frequently Asked Questions

What is Lipocine's stock price forecast for 2023?

0 brokers have issued 12-month price objectives for Lipocine's shares. Their LPCN share price forecasts range from $68.00 to $68.00. On average, they anticipate the company's stock price to reach $68.00 in the next twelve months. This suggests a possible upside of 2,277.6% from the stock's current price.
View analysts price targets for LPCN or view top-rated stocks among Wall Street analysts.

How have LPCN shares performed in 2023?

Lipocine's stock was trading at $6.7626 at the beginning of the year. Since then, LPCN stock has decreased by 57.7% and is now trading at $2.86.
View the best growth stocks for 2023 here.

Are investors shorting Lipocine?

Lipocine saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 130,600 shares, an increase of 52.0% from the August 31st total of 85,900 shares. Based on an average daily volume of 163,900 shares, the short-interest ratio is presently 0.8 days. Currently, 2.5% of the company's shares are short sold.
View Lipocine's Short Interest.

When is Lipocine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our LPCN earnings forecast.

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) issued its quarterly earnings results on Thursday, August, 10th. The specialty pharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by $0.04.

When did Lipocine's stock split?

Shares of Lipocine reverse split before market open on Friday, May 12th 2023. The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Lipocine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Trevena (TRVN), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Biocept (BIOC) and Catalyst Pharmaceuticals (CPRX).

What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

How do I buy shares of Lipocine?

Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lipocine's stock price today?

One share of LPCN stock can currently be purchased for approximately $2.86.

How much money does Lipocine make?

Lipocine (NASDAQ:LPCN) has a market capitalization of $15.22 million and generates $500,000.00 in revenue each year. The specialty pharmaceutical company earns $-10,760,000.00 in net income (profit) each year or ($2.3807) on an earnings per share basis.

How can I contact Lipocine?

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The official website for the company is www.lipocine.com. The specialty pharmaceutical company can be reached via phone at (801) 994-7383, via email at john.woolford@westwicke.co, or via fax at 801-994-7388.

This page (NASDAQ:LPCN) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -